Analysis
Two IPOs show how split 2026's public-listing window really is. Cerebras priced its May IPO at a $56.4 billion valuation and closed its debut day up 68%, backed by real revenue and a multiyear OpenAI compute deal -- the kind of outcome that makes 'the IPO window is open' sound true.
Accelevation's listing months later tells the opposite story. It priced at $660 million, the bottom of its range and a markdown from its original target, despite $727 million in trailing revenue -- and kept sinking through its first days of trading, a story Pulse covered as Accelevation Sinks In Post-IPO Trading Debut.
“Accelevation's listing months later tells the opposite story.”
The gap isn't really about fundamentals -- Accelevation's revenue is comparable in scale to what carried Cerebras, and arguably more mature relative to its raise. It's about profile and narrative: public investors are paying a structural premium for anything that reads as frontier AI with a marquee customer attached, and pricing everything else, infrastructure included, at a discount even when the underlying business is real. Pulse's own coverage of the IPO window opening only selectively found the same pattern: Anthropic and Nscale have filed at enormous targeted valuations but, unlike Cerebras, haven't actually priced -- readiness on paper and readiness the market will reward aren't the same thing.
The nuclear sector is running a similar split in miniature -- private funding into nuclear startups is climbing even as nuclear-adjacent public equities have turned bearish, which Pulse covered separately as Nuclear Startup Funding Is Up, But The Sector's Public Markets Take A Bearish Turn. Private and public investors are pricing the same underlying thesis differently depending on which market they're in, and that gap is the thing to watch heading into 2027's listing calendar.
